SUSTAIN Programme

Timeline

1. 2016 · New England Journal of Medicine
   SUSTAIN-6

   Randomised double-blind trial evaluating cardiovascular outcomes of once-weekly subcutaneous Semaglutide versus placebo in adults with type 2 diabetes at high cardiovascular risk.

Compounds

• Semaglutide

Mechanisms

• GLP-1 Receptor

Research applications

• Glycaemic-control research
• Cardiovascular outcomes research

Comparisons

• Semaglutide vs Retatrutide

  Side-by-side comparison of Semaglutide (GLP-1 mono-agonist) and Retatrutide (GLP-1/GIP/GCG triple agonist) — receptor coverage, structural chemistry, pharmacokinetics, evidence maturity and research applications.

• Semaglutide vs Tirzepatide

  Comparison of Semaglutide (GLP-1 mono-agonist) and Tirzepatide (GLP-1/GIP dual agonist) — receptor coverage, structural chemistry, pharmacokinetics and the published head-to-head evidence base.

• Semaglutide vs Liraglutide

  Comparison of Semaglutide (once-weekly, C18 di-acid) and Liraglutide (once-daily, C16 mono-acid) — shared receptor pharmacology, differing acylation chemistry, pharmacokinetics and evidence base.